

SPECIFICATION AMENDMENTS

Replace paragraph [0035] of the enclosed substitute specification with:

[0035] The initial cDNA and the mutagenesis kit were as described above. For the analysis of the mutation further conservative base exchanges were carried out in order to produce a new restriction site for *BstEII*. For the manufacture of the V531F mutation the following primer was used: GCT TAT GTA ACT GTT AAT GAT TTC GGT TAC CAT CAA CTT ATT AGT CAT TGG TTG CAT AC (SEQ ID NO: 2) (coding strand) and GTA TGC AAC CAA TGA CTA ATA AGT TGA TGG TAA CCG AAA TCA TTA ACA GTT ACA TAA (SEQ ID NO: 3) (complementary strand). In addition the mutant was sequenced and 3 different bacterial colonies were expressed and used for the enzymatic investigations. The expression of LOXpQE-30 was carried out as described previously. The further processing also continued as already described above. The analysis of the fatty acid derivatives produced (the one hydroperoxy group contained in position 6) also continued as described above. The result of the SP- HPLC analysis of the conversion of γ -linolenic acid with V531F is shown in Figure 6. The following Table 2 shows a comparison of the specificity of the wild-type (cslbLOX) with the mutant (cslbLOXV_{531F}).